New York, NY -- (SBWIRE) -- 02/01/2014 -- To receive alerts before the crowd, please take 7 seconds to sign up for our Premium SMS Alerts. Grab your cell phone and text the word "PICKS" to "555888”.
StockMarketIntel.com issues a special report on the following stocks: Gilead Sciences, Inc. (NASDAQ:GILD), Accuray Incorporated (NASDAQ:ARAY), CytRx Corporation (NASDAQ:CYTR), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
Gilead Sciences, Inc. (NASDAQ:GILD) declined -1.07%, trading on 10.83 million shares, to end the trade at $80.65. The stock changed hands in a range of $79.35 to $81.75, bringing its market capitalization to about $123.66 billion. If we look at its trading history of the past 52 weeks, the share price suffered a low of $39.24 and was moved to the maximum level of $84.40. Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead’s primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases, such as hepatitis B and C and cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Asia Pacific.
Will GILD Reach the Bottom after Yesterday’s Correction? Find Out Here
Accuray Incorporated (NASDAQ:ARAY) added 15.26%, to complete the trading session at $10.65, with a total volume of 10.56 million shares. The stock, on average, trades on a volume of 878,662 shares. It floated in a range of $10.00 to $10.71 during the last trading session, with a beta value of 0.91. Its market capitalization now moved to about $797.40 million. In the past 52 weeks, the share price has not declined below $3.76 and above $10.71. Accuray, Inc. manufactures image-guided radiosurgery devices. The Company is based in the United States and its core product, the CyberKnife Stereotactic Radiosurgery System, combines image-guidance with robotics to offer unparalleled flexibility and accuracy.
Will ARAY Continue To Move Higher? Find Out Here
CytRx Corporation (NASDAQ:CYTR) recorded a fall of -13.03% and was in a range of $6.75-$7.39 before closing at $6.94. The stock completed the day with a total volume of 10.45 million shares, versus an average volume of 3.65 million shares. The share price hit its 52-week low of $1.83 and $8.35 was the best price. CytRx Corporation (CytRx) is a biopharmaceutical research and development company specializing in oncology. The Company's oncology pipeline includes three programs in clinical development for cancer indications: INNO-206, tamibarotene and bafetinib. INNO-206 is the Company's tumor-targeted doxorubicin conjugate.
Has CYTR Found The Bottom and Ready To Move Up? Find Out Here
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) declined -7.32% yesterday, bringing its market capitalization around $1.38 billion. The share price, after opening at $6.78, made a high of $6.78 and hovered above $6.31 to end the day at $6.33. The total number of shares that changed hands during the session was 8.98 million shares, as compared to average trading volume of 5.69 million shares. Arena Pharmaceuticals, Inc. (Arena) is a biopharmaceutical company focused on discovering, developing and commercializing drugs that target G protein-coupled receptors. Its wholly owned subsidiary, Arena Pharmaceuticals GmbH (Arena GmbH), has granted Eisai Inc., rights to commercialize BELVIQ in the United States.
Has ARNA Found The Bottom And Ready To Gain Momentum? Find Out Here
To receive alerts before the crowd, please take 7 seconds to sign up for our Premium SMS Alerts. Grab your cell phone and text the word "PICKS" to "555888”.
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list.
Neither StockMarketIntel.com, nor its employees and affiliates are registered as investment advisors or broker/dealers in any jurisdiction whatsoever. Through use of this website viewing or using you agree to hold StockMarketIntel.com, its operators, owners, employees, and affiliates harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Readers should always do their own due diligence and consult a financial professional. StockMarketIntel.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and StockMarketIntel.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled company. Any opinions expressed on this website are statements of judgment as of the date of publication and are subject to change without further notice, and may not necessarily be reprinted in future publications or elsewhere.
Read Full disclaimer at: http://stockmarketintel.com/Disclaimer.htm
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)